Ticagrelor

Thrombosis, Acute Chest Syndrome, Transient Ischemic Attack (TIA) + 8 more
Treatment
20 Active Studies for Ticagrelor

What is Ticagrelor

TicagrelorThe Generic name of this drug
Treatment SummaryTicagrelor, also known as AZD6140, is a medication used to treat and prevent blood clots in patients with heart conditions. It is a derivative of ADP that works by blocking the P2Y12 receptor. Ticagrelor is sold by AstraZeneca under the brand names Brilinta in the US and Brilique or Possia in the EU. It was approved by the European Medicines Agency (EMA) in 2010 and the US Food and Drug Administration (FDA) in 2011.
Brilintais the brand name
image of different drug pills on a surface
Ticagrelor Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Brilinta
Ticagrelor
2011
7

Effectiveness

How Ticagrelor Affects PatientsTicagrelor is a drug used to reduce the risk of heart attack and stroke by preventing blood clots from forming. It is taken twice a day and is generally well tolerated at higher doses. Patients should be warned about potential side effects, such as bleeding, shortness of breath, and slow heart rate.
How Ticagrelor works in the bodyTicagrelor prevents a specific type of receptor from activating and causing platelet aggregation. When this receptor is blocked, it reduces the risk of blood clots forming, which can lead to a reduction in heart attacks and strokes.

When to interrupt dosage

The recommended dosage of Ticagrelor is contingent upon the diagnosed condition, including Stent Placement, Heart Attack and Stroke. The quantity of dosage changes depending on the method of delivery outlined in the table below.
Condition
Dosage
Administration
High Ischemic Risk
, 90.0 mg, 60.0 mg
, Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating
Stroke
, 90.0 mg, 60.0 mg
, Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating
Thrombosis
, 90.0 mg, 60.0 mg
, Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating
Acute Chest Syndrome
, 90.0 mg, 60.0 mg
, Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating
Transient Ischemic Attack (TIA)
, 90.0 mg, 60.0 mg
, Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating
Coronary Disease
, 90.0 mg, 60.0 mg
, Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating
Heart Attack
, 90.0 mg, 60.0 mg
, Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating
High Risk
, 90.0 mg, 60.0 mg
, Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating
Cardiovascular Mortality
, 90.0 mg, 60.0 mg
, Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating
Ischemic Stroke
, 90.0 mg, 60.0 mg
, Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating
Stent Stenosis
, 90.0 mg, 60.0 mg
, Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating

Warnings

Ticagrelor has three contraindications, and it should not be taken when experiencing any of the circumstances outlined in the following table.Ticagrelor Contraindications
Condition
Risk Level
Notes
Intracranial Hemorrhage
Do Not Combine
Hemorrhage
Do Not Combine
Severe Hypersensitivity Reactions
Do Not Combine
Ticagrelor may interact with Pulse Frequency
There are 20 known major drug interactions with Ticagrelor.
Common Ticagrelor Drug Interactions
Drug Name
Risk Level
Description
Abemaciclib
Major
The serum concentration of Abemaciclib can be increased when it is combined with Ticagrelor.
Abrocitinib
Major
The risk or severity of bleeding and thrombocytopenia can be increased when Ticagrelor is combined with Abrocitinib.
Acalabrutinib
Major
The metabolism of Acalabrutinib can be decreased when combined with Ticagrelor.
Albutrepenonacog alfa
Major
The therapeutic efficacy of Albutrepenonacog alfa can be decreased when used in combination with Ticagrelor.
Alectinib
Major
The metabolism of Alectinib can be decreased when combined with Ticagrelor.
Ticagrelor Toxicity & Overdose RiskSigns of an overdose on ticagrelor include bleeding, nausea, vomiting, diarrhea, and pauses in the heartbeat. Treatment for overdose includes monitoring the patient's heart rate and providing supportive care. Dialysis is not expected to be effective in removing ticagrelor from the bloodstream because it binds strongly to proteins.
image of a doctor in a lab doing drug, clinical research

Ticagrelor Novel Uses: Which Conditions Have a Clinical Trial Featuring Ticagrelor?

84 active trials are evaluating the potential of Ticagrelor in providing relief from Acute Chest Syndrome, Cardiovascular Mortality and Myocardial Infarction.
Condition
Clinical Trials
Trial Phases
Cardiovascular Mortality
0 Actively Recruiting
Acute Chest Syndrome
2 Actively Recruiting
Not Applicable, Phase 2
High Risk
0 Actively Recruiting
Thrombosis
0 Actively Recruiting
Transient Ischemic Attack (TIA)
2 Actively Recruiting
Phase 4, Not Applicable
Coronary Disease
1 Actively Recruiting
Not Applicable
Heart Attack
23 Actively Recruiting
Not Applicable, Phase 1, Phase 4, Phase 2, Early Phase 1, Phase 3
Stent Stenosis
0 Actively Recruiting
High Ischemic Risk
0 Actively Recruiting
Stroke
6 Actively Recruiting
Not Applicable, Phase 1
Ischemic Stroke
26 Actively Recruiting
Phase 2, Phase 3, Not Applicable, Phase 1

Ticagrelor Reviews: What are patients saying about Ticagrelor?

5Patient Review
4/8/2014
Ticagrelor for Myocardial Reinfarction Prevention
So far, this medication has been working great for me. I have had a few bruises, but that's the extent of the side effects I've experienced.
4.7Patient Review
5/20/2015
Ticagrelor for Treatment to Prevent a Blood Clot in a Vascular Stent
I've been using this medication since July and it has helped me a lot. I've had two stents put in as a result of my previous health problems.
4Patient Review
2/24/2013
Ticagrelor for Blood Clot Prevention Following Percutaneous Coronary Intervention
I've only been taking this for less than a month, but I haven't had any negative experiences yet.
3.3Patient Review
8/10/2021
Ticagrelor for Treatment to Prevent a Blood Clot in a Vascular Stent
I had some bruising, but nothing too severe. I was able to go back to my regular activities quickly.
3Patient Review
9/23/2011
Ticagrelor for Blood Clot Prevention Following Percutaneous Coronary Intervention
I've only recently started taking this medication, but so far it's been okay.
2.7Patient Review
11/3/2013
Ticagrelor for Blood Clot Prevention Following Percutaneous Coronary Intervention
I had a stent placed in my one 60% blocked artery following a heart attack three weeks ago. I have been feeling heavy breathing and had a massive nose bleed last week where the artery in my nose burst and couldn't be stopped. I had to get emergency e,n,t specialist at Auckland Hospital who was able to stop the bleed after two days. This is a very risky drug, in my opinion.
2.3Patient Review
8/13/2015
Ticagrelor for Acute ST Elevation Myocardial Infarction
This has had a negative effect on my breathing.
1Patient Review
9/24/2019
Ticagrelor for Treatment to Prevent a Blood Clot in a Vascular Stent
I felt very heavy breathing and short of breath after taking the first dose. I'm afraid of the possible side effects.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about ticagrelor

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is ticagrelor a beta blocker?

"The active drug in Brilinta is not a beta-blocker; it is ticagrelor, an antiplatelet drug."

Answered by AI

Is ticagrelor an anticoagulant?

"There are two types of anticoagulants: Plavix (clopidogrel bisulfate) and Brilinta (ticagrelor). These blood thinners inhibit aspects of blood clotting and are used to treat patients with acute coronary syndrome, heart attack (myocardial infarction), peripheral vascular disease, and ischemic strokes."

Answered by AI

Is ticagrelor the same as Plavix?

"Brilinta appears to be more effective than Plavix in reducing the percentage of CV death, MI or stroke in the first year of treatment, though Brilinta patients had more breathing difficulties as a side effect."

Answered by AI

Is ticagrelor same as aspirin?

"The new study found that ticagrelor is not more effective than aspirin in preventing cardiovascular events 90 days after an initial stroke. This is an important finding, as it provides new insights into the best course of treatment for patients who have experienced a stroke or TIA."

Answered by AI

Is Plavix the same as ticagrelor?

"Ticagrelor, or Brilinta, may be slightly more effective than Plavix in reducing the percentage of cardiovascular death, myocardial infarction, or stroke in the first year of treatment. However, patients taking Brilinta were more likely to experience difficulty breathing as a side effect compared to those taking Plavix."

Answered by AI

What is ticagrelor drug used for?

"Ticagrelor helps to prevent the formation of blood clots by making it easier for blood to flow through the veins. This is especially helpful for people who are at increased risk for blood clots."

Answered by AI

Clinical Trials for Ticagrelor

Image of St Boniface Hospital in Winnipeg, Canada.

Remote Home Monitoring for Heart Attack

18+
All Sexes
Winnipeg, Canada
Heart attacks are one of the top causes of death in Canada, with over 2,100 cases treated each year in Manitoba. Even though hospital care has improved, the period after going home is still risky. Many patients feel anxious and unsure about their recovery, and without enough support, they often end up back in the emergency department (ED). This is an even bigger challenge for people in rural areas, where getting follow-up care can be much harder. Filling these gaps is important to help patients get better and to reduce stress on the healthcare system. In a previous study, the investigators found that extra support made a big difference: only 8% of participants using a digital health tool returned to the ED within 30 days, compared to 22% of participants without it. Now, the investigators want to expand this study across Manitoba to see if digital health tools can help more people recover safely at home. The investigators will compare two types of follow-up care: education only versus education with extra support (like symptom tracking and virtual appointments). The investigators will look at how this affects hospital visits, mental well-being, and healthcare costs. The goal is to create a better support system for people after a heart attack, leading to healthier recoveries, less strain on hospitals, and better care for Manitobans - no matter where they live.
Waitlist Available
Has No Placebo
St Boniface Hospital
Image of Baystate Medical Center in Springfield, United States.

Consent Approaches for Heart Disease Rehabilitation

18+
All Sexes
Springfield, MA
Cardiac Rehabilitation is a lifestyle and exercise program for patients with heart disease. Cardiac Rehabilitation is strongly recommended in guidelines, but only 30% of eligible patients attend. New strategies are needed to help more patients attend cardiac rehabilitation. In this study, the investigators will see if using an $50 incentive, case management, text messages, and physical activity coaching combined into a single intervention will help more patients attend cardiac rehabilitation. In preparation for a larger trial, patients will also be randomly assigned to four different ways of seeking their permission to be in a research study. The investigators will see if these approaches affect how many people participate in the research project. The two main goals of this study is to understand: 1. If the consent approach type impacts participation rates in the research study 2. If the multi-component intervention (case management, financial incentives, text messages, and physical activity coaching) improves cardiac rehabilitation participation within 3 months.
Waitlist Available
Has No Placebo
Baystate Medical CenterQuinn R Pack, MD, MSc
Have you considered Ticagrelor clinical trials? We made a collection of clinical trials featuring Ticagrelor, we think they might fit your search criteria.Go to Trials
Image of University of South Florida (USF) in Tampa, United States.

Balloon vs Conventional Guide Catheters for Stroke

18+
All Sexes
Tampa, FL
The purpose of this clinical trial is to study the two main types of approaches used in stroke thrombectomy and to investigate if one approach is more effective than the other, as this is currently not known. This study will be conducted in adults who have been diagnosed with an acute ischemic stroke and who are undergoing a thrombectomy for the treatment of their stroke. The main questions it aims to answer are: * Does the use of a balloon guide catheter versus a conventional guide catheter lower the time needed to restore blood flow in the blocked vessel in the brain * To help researchers better understand the technical, clinical, and procedural outcomes associated with using a balloon guide catheter versus a conventional guide catheter in stroke thrombectomy Participants will be asked to * Share their medical history and imaging data that is collected as part of their routine medical care * Undergo a mechanical thrombectomy as part of their routine medical care * Answer some questions about their neurological functioning at 3 months (90 days) post hospitalization
Recruiting
Has No Placebo
University of South Florida (USF)
Image of Virginia Commonwealth University in Richmond, United States.

Endovascular Treatment for Stroke

18+
All Sexes
Richmond, VA
Endovascular therapy (EVT) has proven to be more beneficial for patients with AIS caused by large vessel occlusions (LVO) than medical management alone. A recent meta-analysis of 5 RCTs showed that EVT significantly reduced disability at 90 days compared to medical management \[1\]. Despite its obvious benefits, patients may have neurological deterioration despite successful thrombectomy due to ischemia progression, intracranial hemorrhage, re-occlusion, or vasogenic edema. The incidence of early neurological deterioration (END) following EVT for acute stroke has been reported to be ranging from 14.1-35.2% with some studies defining END up to 7 days and some restricting the definition between 6-72 hours post thrombectomy. A small proportion of these patients, approximately 5.9-10.5%, experienced sICH following EVT. Whether END occurs due to ischemic or hemorrhagic it leads to worse outcomes.
Waitlist Available
Has No Placebo
Virginia Commonwealth UniversityAarti Sarwal
Have you considered Ticagrelor clinical trials? We made a collection of clinical trials featuring Ticagrelor, we think they might fit your search criteria.Go to Trials
Image of Abcentra Investigational Site in Los Angeles, United States.

Orticumab for Heart Attack

18+
All Sexes
Los Angeles, CA
The goal of this clinical trial is to determine the clinical effect of orticumab treatment on inflammation in study participants with prior myocardial infarction who have elevated coronary inflammation based on CCTA. The main question it aims to answer is: Clinical effects of orticumab treatment on inflammation of the coronary artery parameters measured with CCTA Researchers will compare the effects with placebo group after 6 months of treatment Participants will Keep the planned study visit appointments Provide complete information about medical and medical history Speak to the study doctor before changing any of non-study treatments, including starting new medications, receiving any vaccinations, or setting out to join any other clinical studies
Phase 2
Recruiting
Abcentra Investigational Site (+6 Sites)Abcentra
Image of The Ohio State University Wexner Medical Center in Columbus, United States.

Health Coaching for Cardiovascular Disease

18+
All Sexes
Columbus, OH
For patients discharged with a diagnosis of cardiovascular disease coronary artery disease resulting in myocardial infarction and/or congestive heart failure, this study will evaluate if the addition of 12 virtual health coaching sessions over the course of 16 weeks will improve physiological, psychological, and social health outcomes, prove acceptable and satisfactory for these patients with CVD, decrease CVD-related questions and concerns sent to the provider via MyChart, and reduce hospital readmission rates over a 90-day period as compared to patients discharged with the same diagnosis who receive standard post-discharge care. The study will also evaluate the perceptions of physician and advanced practice providers related to the health coach as part of the interprofessional team and the amount of time spent addressing CVD-related patient questions and concerns via MyChart messages.
Waitlist Available
Has No Placebo
The Ohio State University Wexner Medical CenterBeth Steinberg, PhD, RN
Image of Memorial Hermann Hospital in Houston, United States.

Tenecteplase for Stroke

18 - 80
All Sexes
Houston, TX
In this pilot safety study, the investigators will give a second dose of Intravenous Tenecteplase (IV TNK) to patients receiving the initial TNK dose within 3 hrs of last known normal (LKN), have a baseline National Institutes of Health Stroke Scale (NIHSS) \> 6, and who do not clinically improve within 45 minutes of the first dose, or who improve but then deteriorate, and can still be treated within 4.5 hours from LKN. Patients will require a second computed tomography (CT) scan to rule out any bleeding, and meet the usual inclusion and exclusion criteria for TNK treatment, before the second dose which must be given within 4.5 hrs of LKN. Both TNK doses will be 0.25 mg/kg. The initial TNK dose may be given on the Mobile Stroke Unit (MSU) or Emergency Department (ED), and the second dose in the ED. Informed consent will be obtained before the second dose is given. The primary outcome will be symptomatic intracranial hemorrhage (sICH) (SITS-MOST criteria) or serious systemic bleeding within 36 hours. Secondary outcomes will be any intracranial hemorrhage, any bleeding, discharge NIHSS and modified Rankin Score (mRS), and mRS at 90 days (sliding dichotomy). 20 patients will be enrolled. Enrollment will be stopped if more than 3 sICH occur (\> 80% confidence that sICH rate is \> 5%. If successful, this study will be followed by a larger phase 2b controlled safety confirmation and pilot efficacy study,
Phase 1
Waitlist Available
Memorial Hermann HospitalGenentech, Inc.
Have you considered Ticagrelor clinical trials? We made a collection of clinical trials featuring Ticagrelor, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security